Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:01 PM.
Here’s what investors need to know about the announcement.
Earnings
Lineage Cell Therapeutics beat estimated earnings by 25.0%, reporting an EPS of $-0.03 versus an estimate of $-0.04.
Revenue was down $2.85 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.01 which was followed by a 2.05% drop in the share price the next day.
Here’s a look at Lineage Cell Therapeutics’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.04 | -0.03 | -0.04 | -0.03 |
| EPS Actual | -0.03 | -0.04 | -0.04 | -0.04 |
| Revenue Estimate | 2.57M | 3.90M | 3.68M | 7.32M |
| Revenue Actual | 1.90M | 3.00M | 4.55M | 5.24M |
To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
